CN113614112A - MuSK抑制 - Google Patents

MuSK抑制 Download PDF

Info

Publication number
CN113614112A
CN113614112A CN201980074121.1A CN201980074121A CN113614112A CN 113614112 A CN113614112 A CN 113614112A CN 201980074121 A CN201980074121 A CN 201980074121A CN 113614112 A CN113614112 A CN 113614112A
Authority
CN
China
Prior art keywords
seq
binding
antibody
musk
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980074121.1A
Other languages
English (en)
Chinese (zh)
Inventor
西尔韦尔·马里亚·万德尔马雷尔
约翰内斯·贾斯特斯·赫拉德·马里亚·费斯胡伦
马丁纳·热拉尔迪纳·马里亚·胡伊贝斯
雅各布·扬·普隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2021589A external-priority patent/NL2021589B1/en
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Publication of CN113614112A publication Critical patent/CN113614112A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980074121.1A 2018-09-10 2019-09-05 MuSK抑制 Pending CN113614112A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2021589A NL2021589B1 (en) 2018-09-10 2018-09-10 MuSK inhibition
NL2021589 2018-09-10
NL2023119 2019-05-13
NL2023119 2019-05-13
PCT/NL2019/050576 WO2020055240A1 (en) 2018-09-10 2019-09-05 Musk inhibition

Publications (1)

Publication Number Publication Date
CN113614112A true CN113614112A (zh) 2021-11-05

Family

ID=68138766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980074121.1A Pending CN113614112A (zh) 2018-09-10 2019-09-05 MuSK抑制

Country Status (8)

Country Link
US (1) US20220002438A1 (https=)
EP (1) EP3850014A1 (https=)
JP (2) JP2022500387A (https=)
CN (1) CN113614112A (https=)
AU (1) AU2019337338A1 (https=)
CA (1) CA3112288A1 (https=)
IL (1) IL281409A (https=)
WO (1) WO2020055240A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114487448A (zh) * 2022-01-21 2022-05-13 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015615A2 (en) * 2001-08-15 2003-02-27 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
CN1991366A (zh) * 2005-12-29 2007-07-04 财团法人工业技术研究院 诊断重症肌无力症的方法及其所用的试剂盒
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
CN103826659A (zh) * 2011-06-20 2014-05-28 圣路易斯大学 用于治疗的靶向神经肌肉接头
US20150050289A1 (en) * 2011-11-14 2015-02-19 New York University Muscle specific receptor kinase and modulation thereof
CN108368486A (zh) * 2015-10-07 2018-08-03 纪念斯隆-凯特琳癌症中心 鉴定神经肌肉接头活动的调节剂的体外方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP2011207769A (ja) * 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2015039015A2 (en) * 2013-09-13 2015-03-19 New York University Methods for treating muscle specific receptor kinase myasthenia gravis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015615A2 (en) * 2001-08-15 2003-02-27 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
CN1991366A (zh) * 2005-12-29 2007-07-04 财团法人工业技术研究院 诊断重症肌无力症的方法及其所用的试剂盒
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
CN103826659A (zh) * 2011-06-20 2014-05-28 圣路易斯大学 用于治疗的靶向神经肌肉接头
US20150050289A1 (en) * 2011-11-14 2015-02-19 New York University Muscle specific receptor kinase and modulation thereof
CN108368486A (zh) * 2015-10-07 2018-08-03 纪念斯隆-凯特琳癌症中心 鉴定神经肌肉接头活动的调节剂的体外方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAARTJE G HUIJBERS ET AL: "MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4", PNAS, vol. 110, no. 51, pages 20783 - 20788 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114487448A (zh) * 2022-01-21 2022-05-13 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用

Also Published As

Publication number Publication date
CA3112288A1 (en) 2020-03-19
JP2025016653A (ja) 2025-02-04
EP3850014A1 (en) 2021-07-21
AU2019337338A1 (en) 2021-04-08
US20220002438A1 (en) 2022-01-06
JP2022500387A (ja) 2022-01-04
WO2020055240A1 (en) 2020-03-19
IL281409A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
KR102821932B1 (ko) 항-ccr8 항체 및 이의 용도
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
KR20190083356A (ko) 시누클레인병증의 치료를 위한 제제, 용도 및 방법
KR20160065981A (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
US10919962B2 (en) Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodies
JP6863892B2 (ja) 脳卒中を治療又は予防する方法
CN104093738A (zh) 抗asic1抗体及其使用
CN108350079A (zh) 用于治疗神经学和其它病症的结合激动剂
FR3075200A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
JP2022527373A (ja) Ｒｅｔを結合するヒト抗体およびその使用方法
WO2023143425A1 (zh) 改善认知障碍的方法
KR102731135B1 (ko) 말초신경장애, 또는 말초신경장애 혹은 성상세포장애가 인정되는 질환에 따른 동통의 예방 또는 치료 방법
JP2025016653A (ja) Ｍｕｓｋ阻害
US20240043562A1 (en) Musk activation
NL2021591B1 (en) MuSK activation
NL2021589B1 (en) MuSK inhibition
TW202144425A (zh) 特異性抗原結合分子，其製備方法及醫藥用途
CN111234021B (zh) 一种抗ccr5抗体及其在治疗肿瘤中的应用
WO2026044246A1 (en) Anti-cadherin-17 antibodies and use thereof
KR20240015800A (ko) 뇌신경계 질환을 치료하기 위하여 혈관뇌장벽을 통과할 수 있는 이중특이적 항체와 결합체
RU2809500C2 (ru) СВЯЗЫВАЮЩИЙ RGMa БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ
KR20240015200A (ko) 뇌신경계 질환 치료하기 위한 병용투여용 항체 및 이를 포함하는 약학조성물
KR20230124910A (ko) 염증성 피부 상태 치료 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211105